AU686210B2

AU686210B2 – Eosinophil chemotaxis inhibitor
– Google Patents

AU686210B2 – Eosinophil chemotaxis inhibitor
– Google Patents
Eosinophil chemotaxis inhibitor

Download PDF
Info

Publication number
AU686210B2

AU686210B2
AU72926/94A
AU7292694A
AU686210B2
AU 686210 B2
AU686210 B2
AU 686210B2
AU 72926/94 A
AU72926/94 A
AU 72926/94A
AU 7292694 A
AU7292694 A
AU 7292694A
AU 686210 B2
AU686210 B2
AU 686210B2
Authority
AU
Australia
Prior art keywords
group
hydrogen atom
atom
alkyl group
formula
Prior art date
1993-09-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU72926/94A
Other versions

AU7292694A
(en

Inventor
Yasuko Ashida
Tatsumi Matsumoto
Akio Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1993-09-21
Filing date
1994-09-12
Publication date
1998-02-05

1994-09-12
Application filed by Takeda Chemical Industries Ltd
filed
Critical
Takeda Chemical Industries Ltd

1995-04-06
Publication of AU7292694A
publication
Critical
patent/AU7292694A/en

1998-02-05
Application granted
granted
Critical

1998-02-05
Publication of AU686210B2
publication
Critical
patent/AU686210B2/en

2014-09-12
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

A61K31/50—Pyridazines; Hydrogenated pyridazines

A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

A61K31/50—Pyridazines; Hydrogenated pyridazines

Description

P/00/011 Regulation 3.2
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT 0*
S.
*0 *0 Invention Title: EOSINOPHIL CHEMOTAXIS INHIBITOR o The following statement is a full description of this invention, including the best method of performing it known to us: GH&CO REF: P09027-LU:VNV:RK lyB~s~ asl~s~AL~I auarra~Al”s~s- This invention relates to a method of treating or preventing a disease involving eosinophilic infiltration or eosinophilia, such as allergic rhinitis, atopic dermatitis, etc. using a condensed pyridazine derivative or a salt thereof.
In allergic diseases, various chemical mediators such as leukotrienes B 4
C
4 and D 4 prostaglandins E 2
F
2 and I2, thromboxane Az, platelet activating factor (PAF), histamine, >bparin, serotonin, allyl sulfatase, neutrophil chemotactic factor (NCF), eosinophil chemotactic factor (ECF-A), etc. are released from mast cells at the local sites of reaction to cause allergic responses. These allergic responses can be controlled by inhibiting the release of such chemical mediators or antagonizing their actions. These chemical mediators further trigger the chemotaxis of eosinophils, S 20 -neutrophils, lymphocytes, monocytes and macrophages and .induce allergic responses of the infiltrated cells.
The eosinophils, in particular, reach high levels in the circulating blood and nasal discharge and G. J.
Gleich and coworkers Allergy Clin. Immunol. S 25 412-415, 1987″ report that eosinophilic infiltration is involved in a great measure in atopic dermatitis, allergic rhinitis and other allergic diseases.
Furthermore, an elevation of eosinophil count is found in parasitogenic diseases and eosinophilia and it is not true that all antiallergic agents inhibit eosinophil infiltration.
Meanwhile, EP-A-381132, EP-A-440119 and EP-A- 444549, among others, describe compounds each consisting of an imidazopyridazine skeleton and a side chain attached to the skeleton through a hetero-atom and EP-A-548923, for instance, describes compounds each LI~ ~C ~rrl Ip Fara~ aa~oaramara~a~ -ar~llr~-r~~~-il 2 consisting of an imidazopyridazine and triazolopyridazine skeleton and a side chain attached to the skeleton through a carbon atom. These compounds are known to have antiinflammatory and antiallergic properties based on anti-PAF activity and, as such, may be of value as antiasthmatic agents but there is no reference to inhibition of eosinophil infiltration.
There has been a standing need to this day for a new eosinophil chemotaxis inhibitor, a.therapeutic agent for allergic rhinitis and a therapeutic agent for atopic dermatitis, each of which would show inhibitory activity against eosinophil infiltration, that is to say an inhibitory effect on the chemotaxis of eosinophils, and no potential of causi:ig adverse reactions.
For the purpose of solving the above problems, the inventors of this invention explored in earnest for o.
So: compounds having eosinophil chemotaxis inhibitory activity and discovered that condensed pyridazine *oe 20 derivatives including the following specific and partial chemical structure: a 00o0 wherein the symbols have the same meanings defined hereinafter have unexpectedly high eosinophil chemotaxis inhibitory activity and are of value for the treatment of diseases involving eosinophil infiltration or eosenophilia such as allergic rhinitis and atopic dermatitis. This invention has been developed on the basis of the above findings.
This invention is accordingly directed to A method of treating or preventing a disease involving eosinophilia which comprises administering to a mammal in Sw herein the symbols have the samffective meanings defined 2 hereinafter have unexpectedly high eosinophil chemotaxis inhibitory activity and are of value for the treatment of diseases involving eosinophil infiltration or eosenophilia such as allergic rhinitis and atopic dermatitis. This invention has been developed on the basis of the above findings.
This invention is accordingly directed to A method of treating or preventing a disease involving eosinophilia which comprises administering to a mammal in need of such treatment an effective amount of
~I
~B~i~p BPllra~i~ 3 a ccmpound of the formula: 3 X- (CHz) m Y- (CB)n- SO -Re
S[I]
wherein R 1 represents a hydrogen atom, an optionally substituted lower alkyl group or a halogen atom; either A or B represents a nitrogen atom with the other representing a methine group, or both of them represent a methine group;
R
2 and R 3 independently represent a hydrogen atom or an optionally substituted lower alkyl group, or R 2 and
R
3 taken together with the adjacent may form a 5- to 7-membered ring; X represents a methylene group, an oxygen atom or S(O)p 20 wherein p represents an integer of 0 to 2; Y represents a group of the formula:
R
-C-
14
R
wherein R 4 and R 5 independently represent a hydrogen S” 30 atom or an optionally substituted lower alkyl group or (ii) a divalent group derived from anoptionally substituted 3- to 7-membered homocyclic or heterocyclic ring;
R
6 represents a primary to tertiary amino group; m and n independently represent an integer of 0 to 4, or a salt thereof, a method -as described above in wherein R’ represents a hydrogen atom.
p~ c~ 4 a method as described above in wherein R” and R independently represent a hydrogen atom or a CI-4 alkyl group, a method as described above in wherein X represents an oxygen atom or a sulfur atom, a method as described above in wherein A and B each represent a methine group, a method as described above in wherein A represents a methine group and B represents a nitrogen atom, a method as described above in wherein Y represents a group of the formula
R
5 a
-C-
4 a
R
wherein R 4 a and R 5 independently represent a hydrogen atom or a CI-4 alkyl group, a method as described above in wherein Y represents a C3-7 cycloalkylidene group, a method as described above in wherein R 6 represents an amino group which may be substituted by 1 or 2 substituents selected from the group consisting of an optionally substituted lower alkyl group, an optionally 25 substituted cycloalkyl group and an optionally substituted aryl group or (ii) an optionally substituted cyclic amino group, a method as described above in wherein R 6 represents a group of the formula: 5 wherein R 7 and R 8 independently represent a hydrogen atom, (ii) a CI_ 6 alkyl group which may be substituted by a pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may be substituted by a CI.
4 alkyl group or (iii) a C 3 6 cycloalkyl group or a group of the formula: 9 wherein R 9 represents a hydrogen atom, a C 1 -6 alkyl group, a pyrrolyl group, an imidazolyl group, a pyridyl S. group or a pyrimidyl group, 10 (11) a c-omcition as described above in wherein 6
R
6 represents an amino group, (12)aG a osc: n as described above in wherein R represents a hydrogen atom, (ii) a CL.
6 alkyl group which may be substituted with one or two 15 substituents selected from the group consisting of a hydroxy, amino, carboxyl, nitro, mono- or di-C_ 6 alkyl.mino, C1- 6 alkoxy, C.-6 alkyl-carbonyloxy, phenyl and halogen or (iii) a halogen atom; A represents a methine group; B represents a nitrogen atom;
R
2 and R independently represent a hydrogen atom or a
C
1 6 alkyl group which may be substituted with one or two substituents selected from the group consisting of a hydroxy, amino, carboxyl, nitro, mono- or di-Ci-6 alkylamino, CI_ 6 alkoxy, CI-6 alkyl-carbonyloxy, phenyl and halogen; X stands for an oxygen atom or wherein p is an integer of 0 to 2; Y stands for a group of the formula: c -s 4 6
R
5 a
-C-
R
a wherein R a and R a independently represent a hydrogen atom or a CI.
4 alkyl group or a divalent 3- to 7membered homocyclic ring selected from the group consisting of z, 0, n, 0. 0 :::hydroxy group, (iv) a carboxyl group, a nitro 4* which each may be substituted with 1 to 5 substituents selected from the group consisting of a C.
6 alkyl group, (ii) a mono- or di-C_ 4 alkylamino group, (iii) a hydroxy group, (iv) a carboxyl group, a nitro group, (vi) a CI_ 6 alkoxy group, (vii) a pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may be substituted by one to four C._ 4 alkyl group, and (viii) a halogen; R* represents a group of the formula: wherein R 7 and R 8 independently represent a hydrogen atom, (ii) a C 1 t- alkyl group which may be substituted with one pyrrolyl, imidazolyl, pyridyl or I LI_ 7 pyrimidyl group which may besubstituted by one Ci-4 alkyl group or (iii) a C3-6 cycloalkyl group, or a group of the formula: wherein R 9 represents a hydrogen atom, a C 1 -6 alkyl group, a pyrrolyl group, an imidazolyl group, a pyridyl group or a pyrimidyl group; m stands for an integer of 0 to 4; and n stands for an integer of 0 to 4, (13) A method as described above in wherein R represents a hydrogen atom, R 2 represents a hydrogen atom, R represents a CI-6 alkyl group, A represents a methylene group, B represents a nitrogen atom, X represents an oxygen atom, Y represents a group of the formula S 155
R
51
R
o -C- Rb 4 b 5 b wherein R 4 and R 5 independently represent a Ci-4 alkyl group, R represents an amino group, m represents 1 and S: n represents an integer of 1 to 4, 25 (14) a method as described above in wherein the disease is an allergic rhinitis, a method as described above in wherein the disease is an atopic dermatitis, and so on.
It should be understood that where the compound or a salt thereof contains asymmetric carbon within its structure, it may occur as optically active forms as well as racemic mixtures and that such respective I p -I–I L11 isomers and mixtures of isomers also fall within the scope of this invention.
As used throughout this specification, the term “lower alkyl” generally means, for example, a straightchain or brached CI-6 alkyl group. The CI.
6 alkyl group includes methyl, ethyl, n-propyl, i-propyl, n-butyl, ibutyl, tert-butyl, n-pentyl, n-hexyl, etc. Preferred, among them, are Ci-4 alkyl groups such as methyl, ethyl, n-propyl and i-propyl, etc.
The term “cycloalkyl” generally means, for example, a C 3 -6 cycloalkyl group. The C 3 6 cycloalkyl group includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
The term “aryl” generally means, for example, a 15 C6- 14 aryl group. The C 61 4 aryl group includes phenyl, S. naphthyl, etc. and is preferably phenyl.
The substituent group by which said “lower alkyl” and “cycloalkyl” may be substituted includes hydroxy, amino, carboxyl, nitro, mono- or di-lower alkylamino 20 mono- or di-CI_ 6 alkylamino such as methylamino, ethylamino, propylamino, dimethylamino, diethylamino, etc.), lower alkoxy Ci_- alkoxy such as methoxy, ethoxy, propoxy, hexyloxy, etc.), lower alkylcarbonyloxy
CI.
6 alkyl-carbonyloxy such as 25 acetoxy, ethylcarbonyloxy, etc.), phenyl, and halogen fluorine, chlorine, bromine, iodine, etc.).
These substituents may substitute on the lower alkyl group or cycloalkyl group at any possible position, and two or more of such substituents may be the same or different. The number of these substituents is, for example, about 1 to 4, preferably 1 or 2. And, the “lower alkyl” may have an optionally substituted heterocyclic group as described hereinafter.
The term “heterocyclic group” may be a 5- to 7membered nitrogen-containing heterocyclic group consisting of 1 or 2 aitrogen atoms and the remainder I lr 9 of carbon atoms, such as pyrrolyl, imidazoly’., pyridyl, pyrimidyl, etc., and these heterocyclic groups may respectively have 1 to 4 substituent groups selected from hydroxy, amino, carboxyl, nitro, mono- or di-lower alkylamino mono- or di-C_ 6 alkylamino such as methylamino, ethylamino, propylamino, dimethylamino, diethylamino, etc.), lower alkoxy C,_ 6 alkoxy such as methoxy, ethoxy, propoxy, hexyloxy, etc.), lower alkyl-carbonyloxy
CI-
6 alkyl-carbonyloxy such as acetoxy, ethylcarbonyloxy, etc.), phenyl, halogen (e.g.
fluorine, chlorine, bromine, iodine, etc.) and C 1 -6 alkyl methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, etc.). Particularly preferred substituent groups are a C 1 -4 alkyl group methyl, a.
15 ethyl, n-propyl, i-propyl, etc.).
The substituent group by which said “aryl” group may be substituted includes an optionally substituted lower alkyl, an optionally substituted amino, a 5- to 7-membered cycloamino pyrrolidino, morpholino, 20 piperidino, piperazino, etc.), an optionally substituted amido, hydroxy, carboxy, nitro, lower alkoxy CI- 6 alkoxy such as methoxy, ethoxy, propoxy, etc.), lower alkylcarbonyloxy C 1 6 alkylcarbonyloxy such as acetoxy, ethylcarbonyloxy, etc.) 25 and halogen fluorine, chlorine, bromine, iodine, etc.). These substituents may substitute on the aryl group at any possible positions, and two or more of such substituents may be the same or different. The number of these substituents is, for example, about 1 to 5, preferably 1 to 3.
The “optionally substituted lower alkyl” includes the “lower alkyl” and “its substituents” mentioned above. The preferable examples are a CI-4 alkyl group methyl, ethyl, propyl, isopropyl, etc.).
The substituent group by which said “amino” mentioned above may be substituted includes lower c 10 alkyl Ci.
4 alkyl such as methyl, ethyl, n-propyl, i-propyl, etc.), (ii) lower alkyl-carbonyl
C
1 alkyl-carbonyl such as acetyl, propionyl, butyryl, etc.), (iii) lower alkoxy-carbonyl Ci-4 aikoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.), (iv) halogen fluorine, chlorine, bromine, etc.) and phenyl which may be substituted by 1 to 5 substituent groups selected from the gror.” consisting of halogen fluorine, chlorine, bromine, etc.), CI_ 4 alkyl methyl, ethyl, n-propyl, i-propyl, etc.) and CI- 4 alkoxy (e.g.
methoxy, ethoxy, propoxy, etc.) such as phenyl, 4chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 4-methoxy- 15 phenyl, 3-methoxyphenyl, 2-methoxyphenyl, etc.. The number of these substituents is, for example, 1 or 2.
The preferable examples are a mono- or di-C.4 alkyl group methylamino, ethylamino, dimethylamino, diethylamino, etc.) 20 The substituent group of said “optionally substituted” amido mentioned above includes said species of “optionally substituted lower alkyl” mentioned above. The preferable examples are an acetamido group.
.25 The term “halogen” throughout this specification includes fluorine, chlorine, bromine and iodine.
The term to 7-membered ring formed in combination with the adjacent group” throughout this specification is a 5- to 7-membered ring which nay contain 1 to 4 hetero-atoms selected from among, for example, a nitrogen atom, an oxygen atom, a sulfur atom in addition to carbon atoms. Thus, 5- to 7-membered hydrocarbon rings such as C 5 7 cycloalkene (e.g.
cyclopentene, cyclohexene, cycloheptene, etc.), benzene, etc.; and 5- to 7-membered nitrogen-containing heterocyclic ring such as pyrrole, pyridine, pipe- I i _LII 11 ridine, etc. can be mentioned as the common species.
The term to 7-membered homocyclic ring” throughout this specification, may, for example, be a 3- to 7-membered homocyclic ring consisting exclusively of carbon atoms, i.e. 3- to 7- membered cyclic hydrocarbon. Thus, for example, C3.7 cycloalkanes e.g.
cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, etc.), C_- 7 cycloalkeres e.g. cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, etc.) and benzene can be mentioned as the common species.
The divalent group derived from said to 7membered homocyclic ring” throughout this specification means, for example, a divalent group obtainable by S” 15 removing two hydrogen atoms which bond to one carbon atom in said 3- to 7-membered homocyclic ring or respectively removing one hydrogen atom which bonds to each of two different carbon atoms in said homocyclic ring such as the following: Q Particularly useful are C3- 7 cycloalkylidene groups such as the following: The term to 7-membered heterocyclic ring” i 12 throughout this specification is a 3- to -membered heterocyclic ring which may contain 1 to 4 hetero-atoms selected from among nitrogen, oxygen, sulfur and other atoms in addition to carbon atoms, for instance. Thus, for example, oxetane, tetrahydrofuran, tetrahydropyran, pyrrole, azetidine, pyrrolidine, piperidine, piperazine, tetrahydrothiophene, homopiperidine, morpholine, etc. can be employed.
The divalent group derived from said to 7memberad heterocyclic ring” means a group resulting from either elimination of two hydrogen atoms from a single carbon atom in the 3- to 7-membered heterocyclic ring or elimination of one hydrogen atom from each of two different atoms therein. Thus, for example, the 4 o 15 following groups can be included: 9* *t 4* *0
H
T H c’ H H-
H
.specification means a group resulting from elimination of one hydrogen atom from a nitrogen atom in a ring such as a 3- to 13-membered nitrogen-containing heterocyclic ring which contains one nitrogen atom in addition to carbon atoms and which may also contain one to four hetero atoms, for example, selected from nitrogen, oxygen, sulfur and other atoms. Thus, for example, the following groups can be included: 13 -0 -0 -0.
A preferable example of the “cyclic amino” is a 3to 9-membered cyclic amino group, such as -0 -C -N0 -O The substituent group by which said to 7- 5 membered homocycic ring”, to 7-membered Sheterocyclic ring” or “cyclic amino” may be substituted I include, among others, optionally substituted lower alkyl (preferably, a Cl-4 alkyl group such as methyl, ethyl, etc.); optionally substituted amino (preferably, 10 a mono- or di- C 1 .4 alkylamino group such as methylamino, ethylamino, dimethylamino, diethylamino, etc.); hydroxy; carboxyl; nitro; lower alkoxy C1.6 alkoxy such as methoxy, ethoxy, propoxy, etc.); 5- to 7-membered nitrogen-containing heterocyclic group (e.g.
15 pyrrolyl, imidazolyl, pyridyl or pyrimidyl, which may *e be substituted by 1 to 4 substituents selected from e.g. C1- 4 alkyl such as methy, ethyl, propyl, etc.) and halogen fluorine, chlorine, bromine, iodine, etc.). These substituents may substitute on the ring at any possible position, and two or more of such substituents may be the same or different. The number of these substituents is, for example, about 1 to preferably 1 to 3.
The substituent group for said “optionally substituted lower alkyl” and “optionally substituted 14 amino” includes the same groups as the substitutents mentioned above in “lower alkyl” and “amino”.
Referring to the general formulas presented hereinabove, R’ represents a hydrogen atom, an optionally substituted lower alkyl group or a halogen atom. R 1 is preferably a hydrogen atom or a C 1 -4 alkyl group methyl, ethyl, n-propyl, i-propyl, etc.) and is more preferably a hydrogen atom.
R and R each represent a hydrogen atom or an optionally substituted lower alkyl group, or R 2 and R 3 may, taken together with the adjacent form a to 7-membered ring. R 2 and R 3 independently are preferably hydrogen or a CI.
4 alkyl methyl, ethyl, n-propyl, i-propyl, etc.). Particularly preferred is a 2 15 combination of hydrogen for R and a CI-4 alkyl (e.g.
:methyl, ethyl, n-propyl, i-propyl, etc.) for R 3 Also preferred are cases in which R 2 and R form a 5- to 7membered carbocyclic ring in combination with the adjacent Particularly preferred is the case of 9 20 cyclohexene, benzene or the like.
X stands for methylene, an oxygen atom or S(O)p (p is an integer of 0 to 2, preferably X is preferably an oxygen atom or a sulfur atom and more advantageously an oxygen atom.
25 Either A or B represents a nitrogen atom with the other representing a methine group, or both of A and B represent a methine group. Preferred is a combination of methine for A and nitrogen atom for B, or a combination of methine for both of A and B.
Y represents a group of the formula:
R
4
-C-
R
wherein R 4 and R 5 independently means a hydrogen atom I 15 or an optionally substituted lower alkyl group or (ii) a divalent group derived from an optionally substituted 3- to 7-membered homocyclic or heterocyclic ring.
A preferred example of Y is a group of the formula:
R
4 a
-C-
R
wherein R 4a and R a independently mean a hydrogen atom or a CI- 4 alkyl group such as methyl, ethyl, n-propyl, i-propyl, etc. Preferable examples of R 4 and R 5a 15 include C 1 -4 alkyl such as methyl, ethyl, n-propyl, i- Spropyl and so on.
.Another preferred examples of Y are a C3.7 S. cycloalkylidene group such as the following: The primary to tertiary amino group may, for e* example, be an amino group which may be substituted by 1 or 2 substituant groups selected from the group consisting of an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group and an optionally substituted aryl group, or (ii) an optionally substituted cyclic amino group.
Particularly preferred is a group of the formula R
T
examlebe i) n amno rou whch my b sust; 8e I Pc JLII
I_
16 In the above formula, R 7 and R 8 independently are a hydrogen atom, (ii) a C I, alkyl group which may be substituted by one pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may in turn be substituted by one C1- 4 alkyl group methyl, ethyl, n-propyl, ipropyl, etc.), such as 2-(1-methylpyrrol-2-yl)ethyl, (l-methylimidazolyl)ethyl, etc., or (iii) a C 3 .6 cycloalkyl group cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.). Groups of the following formula are further preferred examples of R 6 9 In the above formula, R 9 represents a hydrogen atom, an optionally substituted lower alkyl group or an optionally substituted heterocyclic group. Preferred examples of R are hydrogen, C1- 4 alkyl methyl, 15 ethyl, n-propyl, i-propyl, etc.) and pyrimidyl. The 6 most useful example of R is an amino group.
The symbol m represents an integer of 0 to 4.
Preferably, m is 1 to 4, and for still better results, m is 1. The symbol n represents an integer of 0 to 4.
20 Preferably n is 1 to 4. The most desirable is a combination of 1 for m and 1 to 4 for n.
The compound or salt thereof can be produced by the per se known processes or processes analogous thereto. For example, the processes described in EP-A- 185346, EP-A440119, EP-A-444549, EP-A-548923 can be used.
Applicant’s Australian patent specification number 654430 discloses the preparation of compounds The compound or a salt thereof can be produced by reacting a compound of the general formula
-~L
17
S
1 wherein Z represents a reactive group; the other symbols have the same meanings defined hereinbefore or a salt thereof with a compound of the general formula: 15 Z2X-(CH2)-Y-(CH2-SO-R [III] wherein Z 2 represents a group which leaves on reacting with Z the other symbols have the same meanings defined hereinbefore or a salt thereof.
20 The reactive group represented by Z I may for example be a halogen atom chlorine, bromine, iodine, etc.), a C6_.
1 arylsulfonyloxy group (e.g.
benzenesulfonyloxy, p-tolylsulfonyloxy, etc.) or a C 1 -4 alkanesulfonyloxy group methanesulfonyloxy).
25 The group which leaves on reacting with Z represented by Z 2 may for example be a hydrogen atom or an alkali metal sodium, potassium, etc.), where X represents an oxygen or sulfur atom, or an alkali metal sodium, potassium, etc.), where X represents -SOor -SOz-.
In this reaction, the compound (III) or a salt thereof is used in a proportion of generally 1 to moles and preferably 1 to 2 moles per mole of the compound (II) or a salt thereof.
This condensation reaction is preferably carried out in the presence of a base. Examples of the base ~e 18 include e.g. an alkali metal hydride such as sodium hydride, potassium hydride, etc.; an alkali metal alkoxide such as sodium methoxide, sodium ethoxide, etc.; an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, etc.; or a carbonate such as sodium carbonate, potassium carbonate and so on.
Furthermore, this reaction can be carried out in an inert solvent, e.g. alcohols such as methanol, ethanol, etc.; ethers such as dioxane, tetrahydrofuran, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; nitriles such as acetonitrile etc.; amides such as dimethylformamide, dimethylacetamide, etc.; and sulfoxides such as dimethyl sulfoxide and so on.
The reaction temperature is generally 10 to 200 0
C
and preferably 50 to 100 0 C. The reaction time is generally 0.5 to 24 hours and preferably 1 to 6 hours.
The compound or a salt thereof can also be produced by reacting a compound of the general formula
S
o..x 25 [IV] wherein all symbols have the same meanings defined hereinbefore or a salt thereof with a compound of the general formula:
(CH
2
(CH
2 -S02-R 6 I 19 wherein all symbols have the meanings defined hereinbefore or a salt thereof.
In this reaction, the compound or a salt thereof is used in a proportion of generally 1 to moles and preferably 1 to 2 moles per mole of compound (IV) or a salt thereof.
This condensation reaction is preferably carried out in the presence of a base. The base that can be used includes alkali metal hydrides such as sodium hydride, potassium hydride etc.; alkali metal alkoxides such as sodium methoxide, sodium ethoxide, etc.; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, etc.; and carbonates such as sodium carbonate, potassium carbonate, etc.; among other bases.
Furthermore, this reaction can be carried out in an inert solvent, e.g. alcohols such as methanol, ethanol, etc.; ethers such as dioxane, tetrahydrofuran, etc.; aromatic hydrocarbons such as benzene, toluene, 20 xylene, etc.; nitriles such as acetonitrile etc.; amides such as dimethylformamide, dimethylacetamide, etc.; and sulfoxides such as dimethyl sulfoxide and the like.
The reaction temperature is generally 10 to 200 0
C
and preferably 50 to 150 0 C. The reaction time is generally 0.5 to 24 hours and preferably 1 to 10 hours.
The compound or a salt thereof can also be produced by reacting a compound of the general formula: 20 2 X- (Cl2)-SO-W
[VI]
wherein W means a leaving group; the other symbols have the same meani.gs defined hereinbefore or a salt thereof with a compound of the general formula: R6-H [VII] wherein R is as defined hereinbefore or a salt thereof.
The leaving group represented by W may for example be a halogen atom chlorine, bromine, iodine, etc.), a C6_10 arylsulfonyloxy group (e.g.
benzenesulfonyloxy, p-tolylsulfonyloxy, etc.), a CI_, 20 alkanesulfonyloxy group methanesulfonyloxy etc.).
Particularly preferred is a halogen atom (e.g.
chlorine, bromine, iodine, etc.).
In this reaction, the compound (VII) or a salt thereof is used in a proportion of generally 1 to 25 moles and preferably 1 to 2 moles per mole of compound (VI) or a salt thereof.
This reaction can be carried out in an inert solvent, e.g. alcohols such as methanol, ethanol, etc., ethers such as dioxane, tetrahydrofuran, etc., aromatic hydrocarbons such as benzene, toluene, xylene, etc., nitriles such as acetonitrile etc., amides such as dimethylformamide, dimethylacetamide, etc., and sulfoxides such as dimethyl sulfoxide and the like.
The reaction temperature is generally -20 to 100 0
C
and preferably -10 to 50 0 C. The reaction time is generally 0.5 to 5 hours and preferably 1 to 3 hours.
~-I
21 When the product compound obtained by any of said processes and is a free compound, it can be converted to a salt in the per se known mannur.
And, when the product compound is a salt, it can be converted to the free compound or a different kind of salt in the per se known manner. The compound or salt thus obtained can be isolated and purified by the known procedures such as solvent extraction, pH adjustment, redistribution, precipitation, crystallization, recrystallization and chromatography and so on. Where said compound or a salt thereof is a mixture of optically active compounds, it can be resolved into the d- and 1-forms by the conventional optical resolution technique.
S 15 The method of producing for the starting compounds [III], and [VII], as well as salts thereof, which are used in the production of compound and its salts of the present invention are described.
20 Incidentally, the salts of these compounds can be salts with inorganic acids hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.)
S
or salts with organic acids acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, 25 succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.). Furthermore, where these compounds have acidic groups such as -COOH, they may form salts with inorganic bases alkali or alkaline earth metals such as sodium, potassium, calcium, magnesium, etc., ammonia and so on) or organic bases tri-C 3 alkylamine such as triethylamine etc.).
The starting corpound [II] or a salt thereof can be synthesized by e.g. the process described in J. Org.
Chem. 39, 2143, 1987 or any process an.- thereto.
22 The starting compound [III] or a salt thereof and the compound or a salt thereof can be synthesized by e.g. the processes described in Chem. Ber. 91, 2130, 1958, J. Org. Chem. 52, 2162, 1987 and Japanese Tokkyo Kokai Koho H3-223287 or processes analogous thereto.
The starting compound [IV] or a salt thereof can be produced by e.g. the process described in Japanese Tokkyo Kokai Koho H3-223287 or any analogous process.
The starting compound [VI] or a salt thereof can be synthesized by reacting a compound [II] or a salt thereof with a compound of the formula: ft 2 Z X (CH 2 )m-Y-(CH 2 )n-SO 2 W [VIII] wherein all symbols have the same meanings defined hereinbefore or reacting a compound [IV] or a salt thereof with a compound of the formula: 20 Z-(CH 2
)-Y-(CH
2 )n-SO 2 W [IX] wherein all symbols have the same meanings defined hereinbefore.
25 In the above reaction the compound [VIII] or a salt thereof is used in a proportion of generally 1 to 5 moles and preferably 1 to 2 moles per mole of the compound [II] or a salt thereof. This reaction can be conducted in the same manner as the above-mentioned reactionl between compound [II] or a salt thereof and compound [III] or a salt thereof.
In the above reaction the compound [IX] or a salt thereof is used in a proportion of generally 1 to moles and preferably 1 to 2 moles per mole of the compound [IV] or a salt thereof. This reaction can be conducted in the same manner as the above-mentioned iI 23 reaction between compound [IV] or a salt thereof and compound or a salt thereof.
The starting compound [VII] or a salt thereof, the starting compound [VIII] or a salt thereof, and the starting compound [IX] or a salt thereof can all be produced by per se known processes or any processes analogous thereto.
The starting compounds and salts thus produced can be isolated by the known procedures such as solvent extraction, pH adjustment, redistribution, precipitation, crystallization, recrystallization, chromatography, etc. The reaction mixture containing the particular compound or salt may be directly submitted to the next reaction.
Alternatively, the compound wherein X is methylene, or a salt thereof, can be produced by reacting a compound of the formula: 20 i 20 S Zr {[ill
M
wherein all symbols have the same meanings defined hereinbefore or a salt thereof with a compound of the formula: QX- (CH z (CH )n-SO,-R 6a
[X]
wherein Q represents a group which an leave on reacting with Z R 6a represents an optionally protected amino group; the other symbols have the same meanings defined hereinbefore or a salt thereof.
I iI 24 Q represents a group which can leave on reacting with Z To be specific, the group represented by ZI includes halogen chlorine, bromine, iodine, etc.), C 6 10 arylsulfonyloxy benzenesulfonyloxy, p-tolylsulfonyloxy, etc.) and C 1 4 alkanesulfonyloxy rethanesulfonyloxy, trifluoromethanesulfonyloxy, etc.), among others. The group represented by Q may for example be a metal halide, of which the halide ion chlorine, bromine and iodine) is preferably iodine and the metl zinc, magnesium, etc.) is preferably zinc.
This condensation reaction is preferably carried o. ut in the presence of a palladium catalyst. The term “palladium catalyst” is used herein to mean any 15 catalyst that can be used for palladium catalyst-cross coupling reactions as described in Accounts of Chemical Research 12, 146-151, 1979; ditto 1, 340-348, 1982; Angew. Chem. Int. Ed. Engl. 25, 508-524, 1986, etc., thus including a palladium-tertiary phosphine complex 20 system or a palladium salt or palladium complextertiary phosphine system. The palladium-tertiary phosphine complex system is a complex of palladium (0 or with a tertiary phosphine such as trialkylphosphines, triarylphosphines, etc., thus 25 including tetrakis(triphenylph sphine)palladium, bis- (triphenylphosphine)palladium bromide, bis(triphenylphosphine)palladium chloride, acetoxybis(triphenylphosphine)palladium, benzylchlorobis(triphenylphosphine)palladium, tetrakis(tributylphosphine)palladium, bis(trimethylphosphine)palladium chloride, bis(triethylphosphine)palladium chloride, bis(tripropylphosphine)palladium chloride, bis(tributylphosphine)palladium chloride and so on.
Preferred are tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium bromide, I H 25 bis(triphenylphosphine)palladium chloride, acetoxybis(triphenylphosphine)palladium and so on.
The palladium salt mentioned above is a salt between a divalent palladium ion and an acid residue, such as palladium chloride, palladium bromide, palladium acetate, palladium nitrate, palladium sulfate and so on. Preferred are palladium chloride, palladium bromide and palladium acetate.
The palladium complex includes not only said palladium-tertiary phosphine complexes but also other complex compounds of palladium (0 or II), thus including bis(phenylethylamine)palladium chloride, bis(benzonitrile)palladium chloride, bis(benzonitrile)palladium bromide, bis- 15 (acetonitrile)palladium chloride and so on. Preferred o a are bis(benzonitrile)palladium chloride, bis(acetonitrile)palladium chloride and so on.
The tertiary phosphine may for example be triphenylphoshine, tributylphosphine, tripropylphosphine, triethylphosphine or trimethylphosphine. A preferred example is triphenylphosphine.
This reaction is preferably carried out in a solvent. The solvent that can be used includes 25 aromatic hydrocarbons such as benzene, toluene, xylene, etc.; ethers such as diethyl ether, tetrahydrofuran, dioxane, etc.; amides such as dimethylformamide, dimethylacetamide, etc.; sulfoxides such as dimethyl sulfoxide, and nitriles such as acetonitrile, among other solvents. The reaction temperature may range from 00 to 200 0 C and is preferably 100 to 100 0 C. The reaction time may range from 30 minutes to 24 hours and is preferably 1 to 3 hours. This reaction can be conducted with advantage in a stream of nitrogen or argon gas. The reaction product can be separated and purified by the per se known procedures such as solvent d 26 extraction, pH adjustment, redistribution, precipitation, crystallization, recrystallization and chromatography.
In conducting this reaction, when R 6a in general formula is an amino group, this amino group is preferably protected using a protective group which is well known in the field of peptide chemistry. The protective group thus includes amide-forming protective groups such as formyl, acetyl, benzoyl, etc.; carbamate-forming protective groups such as tertbutoxycarbonyl, benzyloxycarbonyl, etc.; and imino-type protective groups such as dimethylaminomethylene, benzylidene, p-methoxybenzylidene, diphenylmethylene, and so on. Preferred protective 15 groups are formyl, acetyl and dimethylaminomethylene.
Where the reaction product has any protective group, the group can be removed by the conventional method, for example by hydrolysis with an acid or a base or by catalytic reduction.
20 Incidentally, the starting compound or a salt thereof can be prepared by the per se known processes and analogous processes.
Referring to ,he reactions for synthesis of said compound or a salt thereof or of its starting com- 25 pounds, where any of the reactants has an amino, carboxyl and/or hydroxyl group as a substituent, such substituent group may have been protected with a protective group which is conventionally used in peptide chemistry. In such cases the desired compounds can be obtained by removing the protective groups after the respective reactions.
The protective group that can be used for the ptotection of such an amino group includes unsubstituted or substituted C1- 6 alkyl-carbonyl (e.g.
formyl, acetyl, ethylcarbonyl, etc.), phenylcarbonyl,
C
1
I
6 alkyl-oxycarbonyl methoxycarbonyl,
M
I
27 ethoxycarbonyl, etc.), phenyloxycarbonyl benzoyl etc.), C7- 10 aralkyl-carbonyl benzylcarbonyl etc.), trityl, phthaloyl and so on. The substituents that may be present on the above-mentioned groups may be halogen fluorine, chlorine, bromine, iodine),
C,
6 alkyl-carbonyl methylcarbonyl, ethylcarbonyl, butylcarbonyl, etc.), nitro and so on. The number of substituents may range from 1 to about 3.
The protective group that can be used for the protection of a carboxyl group includes unsubstituted or substituted CI-6 alkyl methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, etc.), phenyl, trityl, silyl and so on. The substituents on such protective groups may be halogen fluorine, chlorine, 15 bromine, iodine), CI_ 6 alkyl carbonyl formyl, acetyl, ethylcarbonyl, butylcarbonyl, etc.), nitro and so on. The number of substituents may range from 1 to about 3.
The protective group that can be used for the 20 protection of a hydroxyl group includes unsubstituted or substituted CI_ 6 alkyl methyl, ethyl, n-propyl, i-propyl, n-butyl, tert-butyl, etc.), phenyl, C 7 aralkyl benzyl), C1 6 alkyl-carbonyl formyl, S ~cetyl, ethylcarbonyl, etc.), phenyloxycarbonyl 25 (benzoyl), C 7 10 aralkyl-carbonyl benzylcarbonyl), pyranyl, furanyl, silyl and so on. The substituent or substituents on such protective groups may be halogen fluorine, chlorine, bromine, iodine), CI-6 alkyl, phenyl, C 7 10 aralkyl benzyl), nitro and so on.
The number of substituents may range from 1 to about 4.
The procedure for eliminating such protective groups may be any known procedure or a procedure analogous thereto and includes processes involving the use of an acid or a base, reduction, UV irradiation, and processes employing hydrazine, phenylhydrazine,
I
28 sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate or other reagent, among other procedures.
The salt of compound according to this invention is preferably a physiologically acceptable acid addition salt. The salt of this type includes salts with inorganic acids hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) and salts with organic acids acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.). Where the compound of this invention has an acidic group such as -COOH, the 15 compound may form salts with inorganic bases (e.g.
alkali metals and alkaline earth metals such as sodium, potassium, calcium, magnesium, etc., and ammonium) and salts with organic bases tri-C,_3 alkylamines such as triethylamine).
20 The compound of formula and a salt thereof have an excellent eosinophil chemotaxis inhibitory activity and can be used with advantage and safety in 0 mammalian animals man, mouse, dog, rat, bovine, etc.), particularly for the treatment of allergic 25 rhinitis, atopic dermatitis and so on. Although the compound or a salt thereof in the present invention may be used as such in the bulk form, it can be administered in the form of a pharmaceutically acceptable preparation which can be prepared using appropriate amounts of the conventional formulation additives selected from among various excipients (e.g.
calcium carbonate, kaolin, sodium hydrogen carbonate, lactose, starch, crystalline cellulose, talc, granulated sugar, porous matrices, etc.), binders (e.g.
dextrin, natural gum, gelatinized starch, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, 29 pullulan, etc), disintegrators (e.g.
carboxymethylcellulose sodium, croscarmellose sodium, crospovidone, low-substitution-degree hydroxypropylcellulose, partially gelatinized starch, etc.), lubricants magnesium stearate, calcium stearate, talc, starch, sodium benzoate, etc.), coloring agents tar color, caramel, iron sesquioxide, titanium dioxide, riboflavine, etc.), corrigents sweeteners, perfumes, etc.), stabilizers sodium sulfite etc.) <.nd preservatives parabens, sorbic acid, etc.) in the per se known manner. When a pharmaceutical composition is used it contains a therapeutically or prophylactically effective amount of said compound or salt thereof. The proportion of compound or a salt based on the total weight of the pharmaceutical composition of the invention is about 0.1 to 100 weight m The pharmaceutical composition may further contain, in addition to said compound [I] 20 or a salt thereof, certain other medicinal substances antiasthmatic agent, antiallergic agent, antiinflammatory agent, etc.). Such concomitant medicinal substances are not restricted in type insofar as the objects of this invention can be accomplished, 25 and can be added in appropriated amounts. The dosage form which can be employed includes tablets (including dragees, film-coated tablets, etc.), pills, capsules, granules, fine granules, powders, syrups, emulsions, suspensions, injectable solutions, inhalants, ointments and so on. These dosage forms can be manufactured by the established pharmaceutical procedures the procedures described in Japanese Pharmacopoeia). Thus, tablets can be manufactured by adding a lubricant to a bulk powder of the active substance or a uniform mixture of the active substance with an excipient, binder, lubricant and/or other formulation II 30 additive and compression-molding the resulting composition. If required, a coloring agent, a corrigent and other auxiliary additive agent can be added. Moreover, tablets can be coated with a suitable coating composition. Injections can be manufactured by dissolving, suspending or emulsifying a calculated amount of the active substance in water for injection, physiological saline, Ringer's solution or the like for an aqueous...system or in a vegetable oil or equivalent for a nonaqueous system to provide unit dosage preparations or sealing it in vials or other containers for injection. The carrier that can be used for pecral dosage forms includes starch, mannitol, crystalline cellulose, carboxymethylcellulose sodium and other substances which are generally used in pharmaceutical manufacture. The carrier or vehicle for injections includes E .distilled water, physiological saline, glucose solution, infusion fluids and so on. Aside from the substances mentioned above, those auxiliary additives .which are generally used in pharmaceutical manufacture can also be added. The active substance of this invention is a safe 25 compound with a low toxic potential (acute toxicity: LD 50 2 g/kg) which inhibits chemotaxis of eosinophils o: and, hence, local eosinophilic infiltration in allergic and inflammatory reactions. Therefore, this invention is useful for the treatment of diseases in which eosinophilic infiltration is involved. More particularly, the invention can be used in the therapy or prevention of various diseases involving eosinophilia in mammalian animals, for example, allergic diseases such as urticaria, atopic dermatitis, allergic rhinitis, hypersensitive pneumonia, etc., diseases of the skin such as eczema, IllillllBILL~sBlrr*rr---------- 31 dermatitis herpetiformis, psoriasis, etc., and respiratory diseases such as simple pulmonary eosinophilia (PIE syndrome). The dosage of the compound or salt thereof used in the method of the invention varies with the patient's age, body weight and condition, the route and frequency of administration and other factors. Taking an adult human weighting 60 kg as an example, 0.1 to 100 mg/kg/day, preferably 1 to 50 mg/kg/day, and for still-..better results, 1 to 10 mg/kg, all as compound or salt thereof, can be administered in a few divided doses. The route of administration may be oral or parenteral. The following test example and examples arq merely intended to illustrate this invention in further detail and should by no means be construed as defining the scope of the invention. Test Example 1 1) Preparation of a guinea pig eosinophil suspension 20 Male Hartley guinea pigs (body weights approx. 300 were intraperitoneally treated with 2 ml of horse serum (Whittaker Bioproducts) once a week for 8 consecutive weeks. Forty-eight (48) hours after the last treatment, 75 ml of physiological saline was S 25 infused into the peritoneal cavity and the lavage was collected and centrifuged at 400 G (1500 rpm) for minutes. The pellet was suspended in 5 ml of Percoll discontinuous density, gradients (specific gravity d=1.07), layered on top of the Percoll suspensions (specific gravity d=1.112:5 ml, d=1.095:10 ml, d=1.090:10 ml, d=1.085:7 ml) and centrifuged (18°C) at 1000 G (2200 rpm) for 30 minutes. The cell layer formed in the boundary zone between the d=1.112 and d=1.095 layers was collected. The collected cell sediment was subjected to hypotonic treatment (suspended in water for 30 seconds) to remove the 32 contaminant erythrocytes. The sediment was washed three times with Hanks solution containing 10 mM HepeE (Dojin Kagaku) (Hanks- Hepes) and suspended in Hanks-Eepes containing 2% (w/v) human serum albumin (Wako Pure Chemical) (Hanks-Hepes- HSA) at a concentration of 2 x 106 cells/ml. The eosinoph,.l purity was 92-96% and the viability of eosinophils was not less than 98%. 2) Chemotaxis inhibition assay A suspension of LTB 4 (Cascade Bioproducts Ltd.) in Hanks-Hepes-HSA, 100 4l, was put in the lower compartment of a blind well chamber and, after placement of a nitrocellulose filter (Sartorius, pore size 8 pm), 100 l of the eosinophil suspension (2 x 15 105 cells) was put in the upper compartment. After 2 hours of reaction in a carbon dioxide gas incubator at 37 0 C, the suspension in the upper compartment was discarded and the filter was dismounted, air-dried on slide glass and fixed with ethanol. The filter was 20 stained with Chromotrope 2R and hematoxylin, made transparent with xylene and embedded in balsam. The cells which had chemotactically migrated to 10 unm from the underside of the filter were counted for 5 fields (high power fields) under a light microscope (400 x 25 magnification). The drug was dissolved in DMSO (dimethyl sulfoxide) and added to both the upper and lower compartments of the chamber. Chemotaxis inhibition rate Sum of chemotactic cells in the presence of the drug 1- x 100 Sum of chemotactic cells in the absence of the drug The test substance was prepared at a concentration of 1 x 10 5 M and the chemotaxis inhibition rate was determined. The results are shown in Tables 1 and 2. 33 Table 1 Inhibitory effect on chernotaxis of guinea pig eosinophi is Al -(CzY (CH2)n I -R Compound R1 No. Rl' R' V~ X Y M D Chenotaxis Re Jnhibition rate 10-5 M a a. a. *O a. a a a I-1 H U1 B a s CH, 1-2 H H H H S CE 2 1-3 H H H H s CH, 1-4 H H 1 H o cff, H H H 11 0 I I 11 NH-K~ 1 1 NBCHzCHr-i~ 11 NH 1 11 NH 2 *9 a. a Oa ~I a aa a 5 Table 2 Inhibitory effect on chemotaxis of guinea pig eosinophils Chemo taxis Compound A B RI RI X Y Mn n Rd inhibition NO. rate 10-5 M C 6 H 11-1 CH x H CH$ 0 -c N1-2 CH N Ri CHA 0 x0 11 &H2 1 1 NH 1 I 34 It is apparent from Tables 1 and 2 that the compound and its salt have potent inhibitory activity against eosinophil chemotaxis. The compound Nos. shown in Tables 1 and 2 are duplicated in the following examples. Example 1 Compound No. II-1 10.0 mg Lactose 60.0 mg Corn starch 35.0 mg Gelatin 3.0 mg Magnesium stearate 2.0 mg Using 0.03 ml of a 10% aqueous solution of gelatin 15 (3.0 mg as gelatin), a mixture of 10.0 mg of compound No. II-1, 60.0 mg of lactose and 35.0 mg of corn starch was granulated through a 1 mm mesh sieve to obtain granules. The granules were dried at 40 0 C and screened again. The resulting granules were mixed with 2.0 mg 20 of magnesium stearate, and the mixture were compressed. S" The resulting core tablets were sugar-coated with an aqueous suspension containing sucrose, titanium dioxide, talc and gum arabic. The resulting tablets were grazed with beeswax to provide coated tablets. 25 Example 2 Compound No. II-1 10.0 mg Lactose 70.0 mg Corn starch 50.0 mg Soluble starch 7.0 mg Magnesium stearate 3.0 mg Using 0.07 ml of an aqueous solution of soluble starch (7.0 mg as soluble starch), a mixture of 10.0 mg of compound No. II-1 and 3.0 mg of magnesium stearate was granulated. The granules were dried and blended with 70.0 mg of lactose and 50.0 mg of corn starch. The resultant composition was compressed to provide tablets. -~s 35 Example 3 Compound No. II-1 5.0 mg Sodium chloride 20.0 mg Distilled water To make 2 ml 5.0 mg of compound No. II-i and 20.0 mg of sodium chloride were dissolved in distilled water, to which distilled water was added up to the total volume of mS. The resulting solution was filtered and filled into 2 ml-ampules under a sterile condition. The filled ampules were sterilized and sealed to provide an injection solution. The method of treating or pre-, nting a disease involving eosinophilia using a compound or a salt thereof according to this invention is of value for the treatment of allergic diseases such as allergic rhinitis and atopic dermatitis. e I* e 0 0o Q Claims (14) 1. A method of treating or preventing a disease involving eosinophilia which comprises administering to a mammal in need of such treatment an effective amount of a compound of the formula: 2-V)YX-C (CCH (CEt) n- SO 2-R' 0* *c 0 o e C *0 C. wherein R' represents a hydrogen atom, an optiona'ly substituted lower alkyl group or a halogen atom; either A or B represents a nitrogen atom with the other representing a methine group, or both of them represent a methine group; R 2 and R 3 independently represent a hydrogen atom or 10 an optionally substituted lower alkyl group, or R 2 and R 3 taken together with the adjacent may form a to 7-membered ring; X represents a methylene group, an oxygen atom or S(O), wherein p represents an integer of 0 to 2; 15 Y represents a group of the formula wherein R 4 and R 5 independently represent a hydrogen atom or an optionally substituted lower alkyl group or (ii) a divalent group derived from an optionally substituted 3- to 7-memrbered homocyclic or heterocyclic ring; R 6 represents a primary to tertiary amino group; P~a~-rr ql 37 m and n independently represent an integer of 0 to 4, or a salt thereof. 2. A method as claimed in claim 1, wherein R' represents a hydrogen atom. 3. A method as claimed in claim 1, wherein R 2 and R 3 independently represent a hydrogen atom or a C 1 -4 alkyl group. 4. A method as claimed in claim 1, wherein X represents an oxygen atom or a sulfur atom. 5. A method as claimed in claim 1, wherein A and B each represent a methine group. 6. A method as claimed in claim 1, wherein A represents a methine group and B represents a nitrogen atom. 7. A method as claimed in claim 1, wherein Y represents a group of the formula: R -C- 4a R wherein R 4a and R 5 independently r-^resent a hydrogen atom or a C'- 4 alkyl group. 8. A method as claimed in claim 1, wherein Y represents a C-7 cycloalkylidene group. 25 9. A method as claimed in claim 1, wherein R' represents an amino group which may be substituted by 1 or 2 substituents selected from the group consisting of an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group and an optionally substituted cyclic amino group. A method as claimed in claim 1, whe-ein R 6 represents a group of the formula 38 wherein R 7 and R 8 independently represent a hydrogen atom, (ii) a C_-6 alkyl group which may be substituted by a pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may be substituted by a CI-4 alkvl group or (iii) a C 3 .6 cycloalkyl group or a group of the formula: -R9 wherein R 9 represents a hydrogen atom, a CI. 6 alkyl group, a pyrrolyl group, an imidazolyl group, a pyridyl group or a pyriimidyl group. 10 11. A mpo ioa as claimed in claim 1, wherein R represents an amino group. 12. A oas claimed in claim 1, wherein R I represents a hydrogen atom, (ii) a Ci-6 alkyl group 1 which may be substituted with one or two substituents. 15 selected from the group consisting of a hydioxy, amino, carboxyl, nitro, mono- or di-Cs. 6 alkylamino, C1. 6 alkoxy, Ci-6 alkyl-carbonyloxy, phenyl and halogen or (iii) a halogen atom; A represents a methine group; B represents a nitrogen atom; R 2 and R 3 independently represent a hydrogen atom or a CI- 6 alkyl group which may be substituted with one or two substituents selected f-om the group consisting of a hydroxy, amino, carboxyl, nitro, mono- or di-Ci_6 alkylamino, C 1 6 alkoxy, CI. 6 alkyl-carbonyloxy, phenyl IhsL-- 39 and halogen; X stands for an oxygen atom or wherein p is an integer of 0 to 2; Y stands for a group of the formula: R wherein R 4a and R 5a independently represent a hydrogen atom or a Ci-4 alkyl group or a divalent 3- to 7- membered homocyclic ring selected from the group 15 consisting of oe K0, 0c 9, 0- *1 and Q which each may be substituted with 1 to 5 substituents selected from the group consisting of a C 16 alkyl group, (ii) a mono- or di-C 4 alkylamino group, (iii) a hydroxy group, (iv) a carboxyl group, a nitro group, (vi) a C 16 alkoxy group, (vii) a pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may be substituted by one to four C 1 alkyl groups and (viii) a halogen atom; R 6 represents a group of the formula: -N 7 whcheahma b ubtiuedwih o sbtiuet PB~FPIIIIIIPB(LPls~P-~-~ls~l 40 wherein R 7 and R 8 independently represent a hydrogen atom, (ii) a Ci_ 6 alkyl group which may be substituted with one pyrrolyl, imidazolyl, pyridyl or pyrimidyl group which may be substituted by one C_-4 alkyl group or (iii) a C 3 -6 cycloalkyl group, or a group of the formula: wherein R represents a hydrogen atom, a Ct s alkyl group, a pyrrolyl group, an imidazolyl group, a pyridyl group or a pyrimidyl group; m stands for an integer of 0 to 4; and n stands for an integer of 0 to 4. 13. A method as claimed in claim 1, wherein R' represents a hydrogen atom, R 2 represents a hydrogen atom, R represents a C 1 6 alkyl group, A represents a 15 methine group, B represents a nitrogen atom, X represents an oxygen atom, Y represents a group of the °formula: S R 5 b -C- 4 b *R wherein R 4 b and R 5b independently represent a C 1 -4 alkyl 6 S 25 group, R 6 represents an amino group, m represents 1 and n represents an integer of 1 to 4. 14. A method as claimed in any one of claims 1 to 13, wherein the disease is an allergic rhinitis. A method as claimed in any one of claims 1 to 13, wherein the disease is an atopic dermatitis. Dated this 3rd day of October 1997 TAKEDA CHEMICAL INDUSTIRES, LTD. By their Patent Attorney GRIFFITH HACK ply l~eq6P~ Abstract A method of treating or preventing a disease involving eosinophilia which comprises administering to a mammal in need of such treatment an effective amount of a compound of the formula: X-(CH2) M Y- (C 2)n-S02-R' R' wherein R1 represents a hydrogen atom, an optionally .o substituted lower alkyl group or a halogen atom; either A or B represents a nitrogen atom with the other representing a methine group, or b6th of them represents a methine group; S R 2 and R 3 independently represent a hydrogen atom or an optionally substituted lower alkyl group, or R 2 and *3 R taken together with the adjacent may form a 5- to 7-membered ring; X represents a methylene group, an oxygen atom or S(O)p wherein p represents an integer of 0 to 2; Y represents a group of the formula -C- 14 R wherein R 4 and R 5 independently represent a hydrogen atom or an optionally substituted lower alkyl group or (ii) a divalent group derived from an optinally substituted 3- to 7-membered homocyclic or heterocyclic ring; R 6 represents a primary to tertiary amino group; m and n independently represent an integer of 0 to 4, or a salt thereof. a e a AU72926/94A 1993-09-21 1994-09-12 Eosinophil chemotaxis inhibitor Ceased AU686210B2 (en) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title JP23476493 1993-09-21 JP5-234764 1993-09-21 Publications (2) Publication Number Publication Date AU7292694A AU7292694A (en) 1995-04-06 AU686210B2 true AU686210B2 (en) 1998-02-05 Family ID=16975996 Family Applications (1) Application Number Title Priority Date Filing Date AU72926/94A Ceased AU686210B2 (en) 1993-09-21 1994-09-12 Eosinophil chemotaxis inhibitor Country Status (10) Country Link US (2) US5922712A (en) EP (2) EP0865790A3 (en) KR (1) KR100280240B1 (en) CN (1) CN1109885A (en) AU (1) AU686210B2 (en) CA (1) CA2132489A1 (en) FI (1) FI944354A0 (en) NO (1) NO307547B1 (en) NZ (1) NZ264479A (en) TW (1) TW304878B (en) Families Citing this family (8) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title EP0781283B1 (en) * 1994-09-16 2001-06-06 Takeda Chemical Industries, Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments CN1248259A (en) 1997-04-25 2000-03-22 武田药品工业株式会社 Condensed pyridazing derivatives, their production and use CA2319426A1 (en) * 1998-03-04 1999-09-10 Kenichirou Kiyoshima Triazolo-pyridazine derivatives for the treatment of chronic obstructive pulmonary diseases WO2000020417A1 (en) 1998-10-06 2000-04-13 Takeda Chemical Industries, Ltd. Fused pyridazine compounds, process for the preparation of the same and uses thereof WO2000023450A1 (en) * 1998-10-21 2000-04-27 Takeda Chemical Industries, Ltd. Fused pyridazine derivatives, process for the preparation of the same and uses thereof WO2001021177A1 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Chemokine/cytokine expression inhibitors EP1243271A1 (en) * 1999-11-11 2002-09-25 Takeda Chemical Industries, Ltd. Nasal drops containing fused pyridazine derivatives EP1966214B9 (en) 2005-12-21 2017-09-13 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators Citations (3) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title EP0185346A2 (en) * 1984-12-21 1986-06-25 Dr. Karl Thomae GmbH Imidazo derivatives, their preparation and medicaments containing these compounds EP0440119A1 (en) * 1990-01-31 1991-08-07 Takeda Chemical Industries, Ltd. Imidazopyridazine compounds, their production and use EP0445549A1 (en) * 1990-03-08 1991-09-11 Precitronic Gesellschaft für Feinmechanik und Electronic m.b.H Pyrotechnic device Family Cites Families (8) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds PH27291A (en) * 1989-01-31 1993-05-04 Takeda Chemical Industries Ltd Imidazolpyrimidazines their production and use US5011835A (en) * 1990-02-07 1991-04-30 Merrell Dow Pharmaceuticals Inc. Substituted triazolopyridazines, pharmaceutical compositions and use DE69106902T2 (en) * 1990-03-01 1995-07-06 Takeda Chemical Industries Ltd Imidazopyridazines, their production and use. KR100226954B1 (en) * 1990-12-14 1999-10-15 슈테펜엘.네스비트 Piperidinyl benzimidazole derivatives, the pharmaceutical composition containing them and the process of them TW211013B (en) * 1991-12-27 1993-08-11 Takeda Pharm Industry Co Ltd LT3200B (en) * 1992-03-18 1995-03-27 Takeda Chemical Industries Ltd Triazolopyridazine methodfor production thereof and use ATE174916T1 (en) * 1992-03-18 1999-01-15 Takeda Chemical Industries Ltd IMIDAZOPYRIDAZINE AS ANTIASTHMATICS 1994 1994-09-09 TW TW083108317A patent/TW304878B/zh active 1994-09-12 AU AU72926/94A patent/AU686210B2/en not_active Ceased 1994-09-17 EP EP98110050A patent/EP0865790A3/en not_active Withdrawn 1994-09-17 EP EP94114661A patent/EP0648491A3/en not_active Withdrawn 1994-09-17 KR KR1019940023814A patent/KR100280240B1/en not_active IP Right Cessation 1994-09-19 NZ NZ264479A patent/NZ264479A/en unknown 1994-09-20 CN CN94115326A patent/CN1109885A/en active Pending 1994-09-20 CA CA002132489A patent/CA2132489A1/en not_active Abandoned 1994-09-20 FI FI944354A patent/FI944354A0/en unknown 1994-09-20 NO NO943494A patent/NO307547B1/en not_active IP Right Cessation 1998 1998-05-01 US US09/070,928 patent/US5922712A/en not_active Expired - Fee Related 1999 1999-02-16 US US09/250,392 patent/US5945419A/en not_active Expired - Fee Related Patent Citations (3) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title EP0185346A2 (en) * 1984-12-21 1986-06-25 Dr. Karl Thomae GmbH Imidazo derivatives, their preparation and medicaments containing these compounds EP0440119A1 (en) * 1990-01-31 1991-08-07 Takeda Chemical Industries, Ltd. Imidazopyridazine compounds, their production and use EP0445549A1 (en) * 1990-03-08 1991-09-11 Precitronic Gesellschaft für Feinmechanik und Electronic m.b.H Pyrotechnic device Also Published As Publication number Publication date AU7292694A (en) 1995-04-06 US5945419A (en) 1999-08-31 EP0865790A2 (en) 1998-09-23 NO307547B1 (en) 2000-04-25 EP0865790A3 (en) 1999-03-10 FI944354A0 (en) 1994-09-20 CA2132489A1 (en) 1995-03-22 NO943494D0 (en) 1994-09-20 KR100280240B1 (en) 2001-02-01 TW304878B (en) 1997-05-11 EP0648491A3 (en) 1995-07-19 NO943494L (en) 1995-03-22 KR950007851A (en) 1995-04-15 EP0648491A2 (en) 1995-04-19 CN1109885A (en) 1995-10-11 NZ264479A (en) 1999-05-28 US5922712A (en) 1999-07-13 Similar Documents Publication Publication Date Title US5366997A (en) 1994-11-22 Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs US20040242673A1 (en) 2004-12-02 Heterocyclic compounds and uses thereof CA2913194C (en) 2021-03-02 Bisulfate of janus kinase (jak) inhibitor and preparation method therefor KR20150058154A (en) 2015-05-28 Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid ES2217580T3 (en) 2004-11-01 ORAL COMPOSITIONS OF LEVOSIMENDAN. US5547970A (en) 1996-08-20 Use of leflunomide for inhibiting tumor necrosis factor alpha AU686210B2 (en) 1998-02-05 Eosinophil chemotaxis inhibitor CN108929329B (en) 2020-12-11 2-azacyclo-5-trifluoromethyl-8-nitrobenz (thio) pyran-4-ones EP0620224B1 (en) 1998-07-15 Triazolopyridazine derivatives, their production and use JP2002544258A (en) 2002-12-24 Ion channel regulator WO2021060453A1 (en) 2021-04-01 Crosslinked optically active secondary amine derivative CA2492110A1 (en) 2004-01-29 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor JP2002544268A (en) 2002-12-24 Ion channel regulator JPH0640989A (en) 1994-02-15 New compound JP3143697B2 (en) 2001-03-07 Eosinophil chemotaxis inhibitor JPH0640990A (en) 1994-02-15 New compound CN113214275B (en) 2023-09-26 Pyranocarbazole alkaloid derivative and application thereof in treating nervous system diseases JP2016520538A (en) 2016-07-14 Fe (III) complexes for the treatment and prevention of iron deficiency and iron deficiency anemia CA1162544A (en) 1984-02-21 Naphthyridine derivatives JPH05331063A (en) 1993-12-14 Antagonist for endothelin receptor JP3049284B2 (en) 2000-06-05 Hydantoin derivatives and preventive and therapeutic agents for diabetic complications and cardiovascular diseases using the same as active ingredients JP2000044584A (en) 2000-02-15 'amino acid derivative'-oxovanadium(iv) complex WO1984000888A1 (en) 1984-03-15 Substituted n-benzenesulfonyloxyphthalimides WO2023235326A1 (en) 2023-12-07 Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors JPH06279287A (en) 1994-10-04 Cancer metastasis inhibitor Legal Events Date Code Title Description 2002-04-11 MK14 Patent ceased section 143(a) (annual fees not paid) or expired
Download PDF in English